Navigation Links
Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs

TEL AVIV, Israel, May 2, 2013 /PRNewswire/ --

Leviticus Cardio, a portfolio company of the Mofet Venture Accelerator, owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with 78% efficiency in vitro.

The animal trials were done using the Leviticus CET system and Jarvik Heart VAD. The CET system performed the energy transfer to the animal body and controlled the VAD pump operation.

In vitro lab tests were conducted using several commercial VAD systems of Thoratec, Heartware, Jarvik Heart and Cleveland Heart . In all these tests, the Leviticus CET system was used to transfer the energy and to control the VAD pumping operation using the Leviticus advanced controller.

Leviticus Cardio was selected to present the results of these in vitro and in vivo tests as part of the scientific program in ISHLT 2013 convention held at Montreal.  

VADs are used to extend the lives of thousands of patients suffering from chronic heart failure or waiting for a heart transplant. Today, VAD patients are connected with wires to an external power supply - risking dangerous infections, repeated hospitalizations and severely limiting mobility. Leviticus Cardio's wireless CET system powers the VAD without wires, thereby avoiding the complications associated with today's technologies. In addition, the Leviticus Cardio's system can easily be removed for limited periods of time to give patients complete freedom of movement without any external device attached.

Michael Zilbershlag, Leviticus co-founder and CEO, stated, "This successful trial is a significant milestone in validating our technology and advancing towards commercialization. We are especially fortunate to be working with Prof. Stephan Schueler , M.D., a leading cardiothoracic surgeon in Europe and with the support from VAD manufacturer Jarvik Heart for the procedures."

Prof. Schueler remarked: "This new device allows us to apply the VAD technology to a wider group of patients outside of the transplant patients' group. For them, to have all the advantages of a wireless technology will have a huge impact on their morbidity and even mortality, and quite obviously on their quality of life."

Media relations:   Efrat Kaduri , Ofir Shpigel Media and Public Relations, +972-4-9535030

SOURCE Leviticus Cardio Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Le cardio pourrait être la clé pour soigner le cancer
2. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
5. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
6. CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
7. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
8. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
9. Interventional Cardiology Devices Market is Expected to Reach USD 25.2 Billion Globally in 2018: Transparency Market Research
10. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
11. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):